Isolator Technology for Aseptic Filling of High Potent Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Isolator Technology for Aseptic Filling of High Potent Products


PIERRE FABRE MEDICAMENT PRODUCTION owns a manufacturing site in the south of France, which has some of the largest experience worldwide with 22 years usage of isolator technology for aseptic filling of high potent freeze-dried injectable products.

Its newest generation of cytotoxic suites were built a few years ago to manufacture new products in compliance with worldwide CGMP and European ATEX regulation. All process operations: dispensing, compounding, filling, lyophilization, capping and external decontamination of the vial, are done under isolator technology. PFMP has developed an innovative filling line with Washing In Place system and Sterilization In Place system of the isolators with built-in Vaporized Hydrogen Peroxyde generator. These two new suites were granted “Most Advanced Facility of the Year” by European Outsourcing Awards in 2008.

PFMP proposes to its partners a full CDMO service with full Development of Product and Active Ingredient, Contract Manufacturing of API and Finish Product including freeze-drying cycle development. Its main objective is always to offer process technology innovation to manufacture future products and to guaranty the compliance with the evolution of the Quality criteria as well as the Environmental and Safety conditions.

PIERRE FABRE MEDICAMENT PRODUCTION
Contact: Franck PAVAN, Outsourcing & Business Development Manager
Email: franck.pavan@pierre-fabre.com
Website: www.aquitaine-pharm.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here